Uses
VII-31 is a potent NEDDylation pathway activator to inhibit the tumor progression in vitro and in vivo. VII-31 induces apoptosis via intrinsic and extrinsic pathways[1].
in vivo
VII-31 inhibits the tumor progression in vivo, while showing no obvious toxicity to mice[1].
| Animal Model: | Mice bearing MGC803 xenograft tumors[1] |
| Dosage: | 50, 100, 150 mg/kg |
| Administration: | Subcutaneous injection; daily for 28 days |
| Result: | The mice had a much smaller tumor compared with vehicle control. The tumor volumes of middle/high dose treated mice at certain time points were evidently decreased comparing with untreated group. |
References
[1] Dong-Jun Fu, et al. Discovery of Novel Tertiary Amide Derivatives as NEDDylation Pathway Activators to Inhibit the Tumor Progression in Vitro and in Vivo. Eur J Med Chem. 2020 Apr 15;192:112153. DOI:
10.1016/j.ejmech.2020.112153
![2-Thiopheneacetamide, N-[(4-methoxyphenyl)methyl]-N-(3,4,5-trimethoxyphenyl)- Structure](https://www.chemicalbook.com/CAS/20200611/GIF/2305757-96-2.gif)
